Keen Therapeutics
科因生物
Keen Therapeutics (科因生物) is an AI-driven drug discovery biotech founded in September 2020 by Yikai Wang (王一恺), a Peking University and Harvard graduate who serves as founder and CEO . FreeS Fund backed it at angel stage and followed on in its August 2021 Series A — a round of tens of millions of RMB led by Sherpa Investment , and per FreeS's own research it completed at least one further financing in 2022 . On the technical side, Keen built its own computational team and platform, and works with fellow FreeS portfolio company Chemical.AI (智化科技) as a downstream partner on synthesis route design and delivery for the molecules it designs — a relationship formalized as a strategic partnership in late 2022 . The most recent coverage in the corpus dates to early 2023, so anything after that isn't reflected here.
AI-generated — may contain errors, please verify.
Coverage
The 6 Questions Young People Care About Most: We Asked 17 Founders | FreeS Fund Youth Festival & Graduation Season Special
Passion and conviction are what carry you through the darkness.
How to Invest in Biotech in 2023? | FreeS Research
Data-driven, cross-disciplinary, bearing fruit — the most certain direction amid uncertainty
Heading Into the Next Spring Amid Winter: 7 Early-Stage Companies Raise Nearly 600 Million RMB | FreeS Family Funding News · Vol 13
Looking forward to working alongside more outstanding founders.
Farewell to a Year of Inflection Points: Will 2022 Be Better? | Li Feng's New Year Outlook
Where the heart leads, steady steps take you far.
"There Will Come a Moment When Technology Defeats Human Experience" | A Conversation with FreeS Fund
"There will come a moment when technology surpasses human experience."
FreeS Fund Earns Ten Honors from Zero2IPO, PEDaily, ChinaVenture & GEW, CVCRI, ChinaRong360, Wanbang RB, and Lancha Consumer | FreeS Matters
Continuously hiring investors
Live at 10 AM Tomorrow | New Opportunities in the Changing Landscape of Drug R&D
See you tomorrow at 10 a.m. sharp.
How Should We Think About the Present and Future of Drug R&D? | FreeS Fund Dialogue Vol. 2 — Final 2 Days to Register
What new variables and opportunities are emerging in the drug development industry?
FreeS Fund Report 25: Food Investment Through the Lens of China's Dietary Structure
What will we eat in the future?
New Opportunities Amid the Great Transformation in Drug R&D | FreeS Fund Dialogue Session 2 Now Open for Registration
Breakthroughs and Acceleration in New Drug R&D
Biotech Firms Raise Nearly 4 Billion Yuan, Consumer Companies Land Over 1.4 Billion | FreeS Family Funding Roundup · August
We've also released three short videos this week — follow us to check them out.
